Brad Hirsch, M.D.

Brad is co-founder of Highlander Health, a firm advancing evidence generation and personalized health care for the new era of medical innovation.  Brad is an oncologist, trialist, entrepreneur, and product leader dedicated to driving transformation at the intersection of research and care. With a deep expertise in value-based care, Brad has dedicated his career to advancing clinical trials and integrating groundbreaking research into everyday clinical practice.

Highlander Health has two parts. Highlander Health Institute is an all-stakeholder platform that creates transparent answers to how best to assure safe, effective, and accessible treatments. Highlander Health Partners invests in companies and technology crucial to personalized care for all.

Prior to Highlander Health, Brad served as Head of Product at Verily, Alphabet’s life sciences company where he led the development and delivery of solutions to accelerate clinical research and improve care. He joined Verily through its acquisition of SignalPath, a clinical trials technology solution, where he was Co-Founder, CEO, and Chair. Research sites and sponsors use SignalPath to run more efficient and effective clinical research studies, and under Brad’s leadership, it was widely adopted by leading health systems and sponsors.

Previously, Brad held roles at Flatiron Health, Texas Oncology, and US Oncology and served on the faculty of Duke University. In addition to his corporate and academic roles, Brad gives back through several philanthropic commitments, including Board roles at the Fuqua School of Business at Duke University, National Outdoor Leadership School (NOLS), St. Mark’s School of Texas, and AT&T Performing Arts of Dallas. He is also on the executive committee for the Clinical Trials Transformation Initiative (CTTI).

Brad is based in Dallas and enjoys spending time in the outdoors with his wife and two children.